Metabolic Myopathies Flashcards

1
Q

metabolic myopathy defect classification

A

*carbohydrates (glycogen storage diseases, GSD)
*lipids (fatty acid transport, fatty acid oxidation, FAO)
*mitochondria (oxidative phosphorylation, OXPHOS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

metabolic myopathy classification - static vs dynamic clinical presentation

A

*static: fixed weakness, progressive; systemic involvement (heart, liver, brain, kidneys); more in newborns and infants
*dynamic: related to exercise (cramping, myalgia, intolerance, myoglobinuria); more in juveniles and adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

glycogen storage diseases (GSD or glycogenoses)

A

*most are autosomal recessive
*carbs are predominantly in liver and muscle tissues
*glucose is not being released and therefore cannot be used as an energy source (unable to create ATP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

GSD type I: Von Gierke disease

A

*glucose-6-phasophate deficiency
*CANNOT GET GLUCOSE OUT OF LIVER
*2nd most common form of GSD
*G6P only found in the liver, so no significant weakness
*pts present early in life with hepatomegaly, renal disease, growth restriction and typical facial features
*patients often have developmental delays

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GSD type I: Von Gierke disease - labs

A

*hypoglycemia
*lactic acidosis
*hyperuricemia
*hyperlipidemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GSD type I: Von Gierke disease - treatment

A

*diet, strict calories
*avoid hypoglycemia
*avoid fructose and galactose
*uncooked starch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GSD type II: Pompe disease - overview

A

*alpha-1,4-glucosidase deficiency (acid maltase deficiency)
*results in glycogen accumulation in the heart, liver, and muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GSD type II: Pompe disease - infantile presentation

A

*generalized weakness
*hypotonia (“floppy baby”)
*macroglossia
*cardiomyopathy
*weak/poor feeding
*respiratory failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

GSD type II: Pompe disease - juvenile presentation

A

*onset within first decade of life
*proximal muscles and calf hypertrophy
*Gower’s sign (Duchenne muscular dystrophy is most common cause of gower’s though)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

GSD type II: Pompe disease - adult presentation

A

*proximal muscle weakness (similar to polymyositis)
*diaphragm involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

GSD type II: Pompe disease - labs

A

*elevated CK
*a-glucosidase activity will be low (usually from dried blood spot test)
*high LFT
*high LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

GSD type II: Pompe disease - treatment

A

*enzyme replacement therapy - alglucosidase alfa every 2 weeks
*one of the few that actually has an effective treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

GSD type III: Cori-Forbes disease - overview

A

*debranching enzyme deficiency
*debranching enzyme has 2 functions:
1) glucanotransferase fxn
2) a-1,6-glucosidase fxn
*subtypes of disease based on enzyme deficiency location and specific activity (a-d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

GSD type III: Cori-Forbes disease - clinical features

A

*weakness noted in 3rd to 4th decade; 50% in DISTAL muscle groups in lower extremities
*ultimately, ventilatory muscles are involved
*can have associated cardiomyopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

GSD type III: Cori-Forbes disease - labs

A

*reduced enzyme function of muscle, fibroblasts or lymphocytes
*elevated CK levels
*high liver function tests (LFTs)
*muscle biopsy: PAS positive vacuoles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GSD type III: Cori-Forbes disease - treatment

A

*low carb, high protein diet to help prevent fasting hypoglycemia
*uncooked cornstarch at bedtime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

GSD type V: McArdle disease - gene/enzyme defect

A

*myophosphorylase deficiency
*associated with gene PYGM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

GSD type V: McArdle disease - clinical presentation

A

*typically seen in childhood or young adults
*exercise intolerance with strenuous activity (weight lifting) or prolonged exercise (jogging, swimming)
*exertional muscle pain, cramping with “second wind” phenomenon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

GSD type V: McArdle disease - labs

A

*excessively high CK levels (50k+), even when patients are not symptomatic
*myoglobinuria
*high LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

GSD type V: McArdle disease - treatment

A

*control exercise (warm up)
*diet, sugar load prior to activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

GSD type VII: Tauri disease

A

*very similar to type V (McArdle): exercise-induced myalgia, cramping, jaundice
*typically is associated with fewer myoglobinuria and rhabdomyolysis
*due to lack of PFK in erythrocytes, can lead to hemolysis
*NO SECOND WIND phenomenon, but “out of wind” phenomenon (giving a sucrose load gives no benefit or makes symptoms worse)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

disorders of lipid metabolism

A

*fatty acids are main source of energy for muscles at rest and following intense exercise or physical activity
*in normal lipid metabolism, fatty acid chains must move from cytoplasm to inner matrix of mitochondria
*long-chain fatty acids need help moving across the membranes
*once within the inner matrix, beta oxidation can occur, ultimately leading to ATP production

23
Q

carnitine transporter deficiency - etiology

A

*defects in OCTN2 (sodium dependent carnitine transporter protein)
*result: carnitine is not able to enter cells/cytoplasm and therefore cannot move fatty acids

24
Q

carnitine transporter deficiency - clinical features

A

*reduced feeding
*hepatosplenomegaly
*AMS (altered mental status)
*cardiomyopathy
*“hypoketotic hypoglycemia” when fasting

25
carnitine transporter deficiency - labs
*low carnitine *low ketones *low glucose *high NH4 *high CK
26
carnitine transporter deficiency - treament
*L-carnitine *avoid fasting *low fat diet
27
CPT1A deficiency - pathophysiology
*CPT1A = carnitine palmitoryltransferase 1 *pathology associated with type A isoform, which is found in the liver
28
CPT1A deficiency - clinical features
*altered mental status (AMS) *hepatomegaly *no muscle symptoms *often triggered by viral illness or fasting
29
CPT1A deficiency - lab findings
*high carnitine *low acylcarnitine *low ketones *low glucose *mild NH4
30
CPT1A deficiency - treatment
*avoid fasting *low fat diet *MCFA
31
CACT deficiency - clinical presentation
*typically seen in neonates (up to 18 months) *cardiac arrhythmias *seizures *severe muscle weakness *hepatic dysfunction *apneic episodes *often triggered by infection, stress, fasting
32
CACT deficiency - labs
*low carnitine *high acylcarnitine *low ketones *low glucose *high NH4 *high CK
33
CACT deficiency - treatment
*low fat diet *avoid fasting *higher carbs *controlled exercise
34
CPT2 deficiency - overview
*most common cause of recurrent myoglobinuria/metabolic myopathy in adults
35
CPT2 deficiency - clinical presentation
*usually in 2nd or 3rd decade of life *intense muscle pain following prolonged fasting, infection, or intense prolonged exertion *neonatal = death
36
CPT2 deficiency - labs
*low carnitine *high acylcarnitine *low ketones *low glucose *high NH4 and CK
37
CPT2 deficiency - treatment
*avoid fasting *low fat diet *high carbs *controlled exercise
38
disorders of fatty acid oxidation
*categorized based on the length of the fatty acid chain *clinical presentations ranging from mild hypotonia in adults to sudden death in infants with hypoketonic hypoglycemia *muscle biopsy often shows excess lipid within fibers *treatment directed at high-carb diets
39
examples of fatty acid oxidation disorders
*VLCAD (VLCA-CoA dehydrogenase deficiency) *LCAD (LCA-CoA dehydrogenase deficiency) *MCAD (MCA-CoA dehydrogenase deficiency) *SCAD (SCA-CoA dehydrogenase deficeincy)
40
clinical features of fatty acid oxidation disorders
*hypoglycemia *hepatomegaly *myopathy
41
labs of fatty acid oxidation disorders
*NORMAL CK other variable
42
mitochondrial myopathies
*related to deletions or depletions of mtDNA and/or nDNA *results in disruptions of oxidative phosphorylation, impaired ATP production *only passed down maternally *muscle biopsy can show ragged red fibers (RRF)
43
Kearns-Sayre Syndrome and Progressive External Ophthalmoplegia (KSS/PEO) - genetics/defect
*single large deletion in mtDNA
44
KSS/PEO - clinical features
*ophthalmoplegia *proximal weakness *respiratory muscle weakness *sensorineural hearing loss *endocrinopathy
45
KSS/PEO - labs
*normal CK *high lactate *biopsy with RRF, COX negative fibers
46
KSS/PEO - treatment
*creatine supplement *surgery (ptosis) *CV support
47
myoclonic epilepsy and ragged red fibers (MERFF) - genetics/defect
*MTTK/ mtDNA point mutation
48
MERFF - clinical features
*epilepsy *proximal weakness *sensorineural hearing loss *optic atrophy
49
MERFF - labs
*normal CK *high lactate *pyruvate *abnormal EEG *red ragged fibers on muscle biopsy
50
MERFF - treatment
*creatine supplementation *AED drugs (tx seizures)
51
mitochondrial myopathy, lactic acidosis and stroke-like episodes (MELAS) - genetics/defect
*MTTL1, MtDNA point mutation
52
MELAS - clinical features
*proximal weakness *stroke-like episodes *migraine headaches, nausea, vomiting, hemiparesis, hemianopsia, cortical blindness *can have seizures/myoclonus *rare eye findings
53
MELAS - labs
*normal or high CK *very high lactate in serum and/or CSF *MRI findings (not localized to a vascular territory)
54
MELAS - treatment
*L-arginine and citrulline *AED drugs (tx seizures)